This case study involves a randomized Phase III study. It examined the study drug in combination with another medication versus chemotherapy in patients with checkpoint inhibitor refractory non-squamous NSCLC.
In this case study, you’ll learn:
- PRA presented a data-driven rationale for the enrollment challenges the sponsor was facing
- We did this by analyzing data intelligence assessing patterns by treatment line and utilizing our therapeutic expertise and local country standard of care knowledge
- PRA worked with the sponsor to amend the protocol to align the inclusion/exclusion criteria with treatment patterns and the usual standard of care
This study proved crucially important to leverage data intelligence and collaborate early during protocol development to ensure feasible enrollment and study success. It produced a greater number of eligible patients, higher enrollment, and a more viable country mix.
The Center for Immuno-oncology, Cellular, and Gene Therapy Fact Sheet
The Center for Immuno-oncology, Cellular, and Gene Therapy leverages our comprehensive experience and cross-functional experts to build…
Ask the Experts: What Does the Future Hold for CRISPR Gene Editing Technology?
Changing a living organism’s DNA sounds like something out of science fiction, but recent strides in genome (gene) editing have given scientists…
Cervical Cancer Awareness Month: Looking to the Future of Treatment
January is Cervical Cancer Awareness Month. In light of this, we share some of the most recent highlights of cervical cancer research.